Quick Answer
Sionna Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $58.45 million for the year ending 2025.
- Sionna Therapeutics, Inc. showed an increase of +54.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Sionna Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $82.75 million | Q2 2024: $44.02 million | Q3 2024: $35.75 million | Q1 2025: $82.70 million | Q2 2025: $40.99 million | Q3 2025: $50.83 million.
- Historical annual values: Fiscal year 2025: $58.45 million | Fiscal year 2024: $37.79 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: